ANALYSIS OF STRUCTURED AND COMMENTED INDIVIDUALIZED DRUGS REVIEWS MADE BY HOSPITAL PHARMACY DEPARTMENT

MJ Gándara-LadronDeGuevara,S. Fénix-Caballero, E. Alegre-del Rey, M. Blanco-Castaño, C. Palomo-Palomo, J. GarciaDeParedes-Esteban, M. Camean-Castillo, E. Ríos-Sanchez, J. Díaz-Navarro, J. Borrero-Rubio.
**HOSPITAL PHARMACY**. **HU PUERTO REAL. (CÁDIZ- SPAIN)**   CP-134

The structured and commented reviews (SCREV) are individual assessments for drugs not included in the Pharmacotherapeutic Guide (NIPG) and off-label drugs requested by prescribers, in order to approve their use

PURPOSE: The objectives were to describe SCREV performed and to estimate the economic impact derived from the recommendation of pharmacy.

MATERIAL AND METHODS:

➢A three-year descriptive retrospective study was designed with SCREV performed in this period.

➢SCREV contained information about indications (NIPG or off-label), efficacy, safety, convenience, costs, including alternatives and cost/utility analysis, with a limit of 40.000€/QALY.

➢The final **recommendation of pharmacy** included :

A — **APPROVAL**

B — **CONDICIONAL APPROVAL**

C — **REFUSAL**

D — **NON-OPPOSITION WITH NEGATIVE OPINION**

In case C, the savings achieved using the average time of treatment were estimated.

In case D, the effectiveness and the economic impact associated to the use of drug were calculated.

RESULTS:

48 SCREV were analyzed , **17** off-label and **31** NIPG. The highest number of requests came from **Oncology (48%).** The recommendations of pharmacy were: **16.6% A, 54.2% B, 18.75% C** and **10.45% D**
The results are summarized in the table:

SCREV N=48	A Approval N=8 *(16.6%)*	B Conditional approval N=26 *(54.2%)*	C Refusal N=9 *(18.75%)*	D Negative opinion N=5 *(10.45%)*
cost 40.000€/ (QALY)	N=2 not calculated:N=6	N=8 not calculated:N=10 lower cost:N=8	N=8 lower cost:N=1	N=1 not calculated: N=4
No Alternatives treatments	N=3	N=13	N=0	N=2

The savings achieved with **C recommendation** were **229.324€.**
The economic impact of **D recommendation** (all of them offered to the patients before request) was **63.447€.** Their effectiveness measured by overall survival (OS), and progression-free survival (PFS) were **OS < 2months**, **PFS <5 months** in all cases.

CONCLUSIONS:

➢ Individual SCREV showed utility for taking complicated decisions about off-label and NIPG drugs use at hospital, with important savings achieved.
➢More than a half of the drugs requests were approved with adjusted conditions of use.
➢The cases with negative opinion of pharmacy showed low effectiveness.